A recent study indicates that individuals who stop using blockbuster weight-loss injections like semaglutide or tirzepatide tend to recover reduced body mass far faster than those who halt conventional diet and exercise programs.
Published data in a leading medical journal points out that while overweight people can lose a large proportion of their total mass while using the jabs, the weight is regained at an estimated rate of nearly a kilo each month after stopping.
"Individuals buying these medications should be cognizant of the risk of rapid rebound weight gain when the therapy is stopped," stated researcher Dr. Susan Jebb.
That rate of regain implies a return to pre-treatment weight within about 18 months.
Comparing Therapies
The research, which reviewed dozens of studies involving over 9,000 of patients, contrasted the effects of GLP-1 agonists with older methods.
Researchers emphasize that individuals who shed pounds through dieting typically experience a more gradual weight regain—around 0.1 kg a month—after stopping.
The Reason for the Quick Regain
Experts believe the way of the drugs explains the amplified rebound.
These medications mimic a body's own chemical called glucagon-like peptide-1, which moderates feelings of fullness.
"Long-term administration of the hormone concentrations several times higher than normal could lead to the body to generate a reduced amount of its endogenous GLP-1, and may also diminish sensitivity to its actions," said Dr. Adam Collins, a dietetics expert.
"Withdrawal of this GLP-1 'fix' means appetite is no longer kept in check, making overeating much more probable."
A Chronic Condition?
Health authorities suggest the injections for people with weight-linked health risks, accompanied by recommended lifestyle changes.
Many experts contend that, given the likelihood of weight regain, the therapy should be considered life-long.
This view is echoed by drug manufacturers, who state that the findings "underscore the chronic character of excess weight," comparing it to managing diseases like high blood pressure.
Patient Experiences
People who have come off the medication report a powerful return of appetite.
"I experienced a switch flipping and I was suddenly ravenous," described one woman.
This difficulty is worsened if users have not established sustainable dietary or behavioural modifications during therapy.
Growing Use
Survey data suggest that millions of adults in the UK have tried these injections in the past year, with desire being substantial.
- Adoption is greater among women than males.
- The middle-aged age group shows the highest level of interest.
- A large proportion access the medications through private prescriptions rather than the NHS.
Ultimately, experts caution that while GLP-1 drugs are powerful tools for shedding pounds, they are not a standalone cure and maintained weight loss hinges on ongoing behavioural changes.
